3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Breast
1
Conditions
Breast Neoplasms
65
Neoplasms
56
Prostatic Neoplasms
44
Lung Neoplasms
35
Colorectal Neoplasms
35
Carcinoma, Non-Small-Cell Lung
24
Pancreatic Neoplasms
21
Hematologic Neoplasms
19
Head and Neck Neoplasms
16
Neoplasm Metastasis
15
Urinary Bladder Neoplasms
12
Ovarian Neoplasms
11
Stomach Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Motor Activity
10
Triple Negative Breast Neoplasms
9
Multiple Myeloma
9
Colonic Neoplasms
9
Melanoma
8
Glioma
8
Anxiety Disorders
8
Uterine Cervical Neoplasms
7
Hematopoietic and Lymphatic System Neoplasm
7
Glioblastoma
7
Gastrointestinal Neoplasms
7
Esophageal Neoplasms
7
Anatomic Stage I Breast Cancer AJCC v8
7
Smoking Cessation
6
Sarcoma
6
Rectal Neoplasms
6
Interventions
Paclitaxel
7
Doxorubicin
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
Bevacizumab
4
durvalumab
3
Radiotherapy
3
Propranolol
3
Docetaxel
3
regorafenib
2
cemiplimab
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Nivolumab
2
Ifosfamide
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trebananib
1
trastuzumab duocarmazine
1
talimogene laherparepvec
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Hemangiosarcoma
×
Standard of Care
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT04055220
2026-02-17
REGOSTA
Centre Leon Berard
Phase NA
Recruiting
168 enrolled